Regenerative pain medicine covers a group of injection treatments that share one idea: rather than suppressing inflammation, they provoke or support the body's own repair process in tissue that has stopped healing properly.
The category includes platelet-rich plasma, dextrose prolotherapy and perineural injection therapy. It is also the area of pain practice where marketing has outrun evidence most comprehensively, which makes an honest account of what each does — and what the trials actually show — more useful than an enthusiastic one.
This reference draws on Empire's regenerative medicine curriculum, taught by Robert Stall, MD, who is board certified in physical medicine and rehabilitation with subspecialty board certification in pain medicine, and completed an ACGME-accredited Interventional Pain and Spine Fellowship at LSU New Orleans. He has practised interventional pain medicine since 2006. It sits under our clinical reference to interventional pain procedures.
Prolotherapy, PRP and PIT are one family, not three
A point that clears up a great deal of confusion at the outset: these are not competing categories. As Stall puts it, “PRP is a subcategory of prolotherapy” — both work by inducing a controlled healing response in tissue that is failing to repair itself.
What separates them is what is injected and, crucially, whether inflammation is the mechanism:
- Dextrose prolotherapy uses hyperosmolar dextrose to provoke a deliberate inflammatory response in pathological tissue.
- Platelet-rich plasma delivers the patient's own concentrated platelets, whose alpha granules release growth factors directly.
- Perineural injection therapy is the outlier — it acts on nerves rather than connective tissue, and Stall is explicit that “it does not require the induction of an inflammatory response.”
The three phases, and why the timeline matters clinically
Healing after prolotherapy or PRP follows a sequence that explains almost every question patients ask afterwards.
Inflammation, days 1 to 3. Cytokines release from activated platelets, or hyperosmolar dextrose provokes inflammation directly. This is when pain exacerbation happens if it is going to — Stall notes that not every patient experiences it, but this phase is when they would.
Proliferation, from about 72 hours to six weeks. Myofibroblasts, fibroblasts and endothelial cells arrive and lay down new type I and type III collagen. Patients start to feel the first improvement here.
And this is where the most important patient instruction in the whole field belongs. The new collagen is, in Stall's description, still “immature and disorganised” — so patients are at increased risk of injury precisely when they begin feeling better. Overworking the area during proliferation is how a good result gets undone.
Remodelling, from two weeks to as long as two years. Collagen cross-links mature and the fibrillar pattern of healthy tendon and ligament re-establishes, replacing the disorganised structure of prior tendinosis. Stall frames this as the actual objective: “the eventual re-establishment of more physiologically normal tissue represents the fundamental and ultimate goal of prolotherapy, including PRP.”
A treatment aiming at a two-year remodelling process should not be judged at two weeks.
The concentration finding that contradicts the marketing
If one piece of evidence deserves to be better known, it is this.
Platelet concentrations from above baseline up to roughly 750,000 platelets per microlitre — about one to four times whole blood — are supported as effective for tissue regeneration by several clinical trials. Above that, Stall states plainly, “there was no evidence that platelet concentrations greater than 750,000 necessarily provided any better tissue regeneration in soft tissue injury.”
More striking: at very high concentrations the effect on bone regeneration was inhibitory, and those subjects “did worse than controls who had no PRP treatment at all.”
So a clinic advertising the highest platelet concentration available is advertising something the evidence does not support, and in one tissue type actively contradicts. This is explored further in why more platelets is not better PRP.
Why two PRP studies can disagree completely
PRP is not one product, and the literature reflects that. Stall is direct about the cause: multiple classification systems exist and “none of these classification systems have been universally accepted as a universal standard, giving rise in part to the confusion.”
Two systems are worth knowing. The first classifies by leukocyte content and fibrin architecture:
- P-PRP — pure PRP: low fibrin matrix, white cells removed
- L-PRP — leukocyte-containing: low fibrin matrix, white cells present
- P-PRF — pure platelet-rich fibrin: no white cells, high fibrin matrix. Popular for orthopaedic indications, particularly knee osteoarthritis
- L-PRF — both white cells and a high fibrin matrix
The second, the PAW system, classifies by Platelet concentration, Activation and White cells — with platelet bands at or below baseline, baseline to 750,000, 750,000 to 1,250,000, and above 1,250,000 per microlitre.
The practical consequence: two trials both labelled “PRP” may have used preparations with opposite leukocyte content and a fourfold difference in platelet concentration. Comparing their results directly is not meaningful, and neither is a clinic's claim to use “PRP” without specifying which.
What the evidence supports, indication by indication
Stall's account is notable for declining to overstate.
Lateral epicondylitis has the strongest single result: one study found a single PRP injection produced significantly greater improvement than corticosteroid, with benefit maintained at two-year follow-up.
Achilles tendon repair augmented with PRP at three times whole blood concentration showed significant improvement in recovered range of motion and return to sport compared with repair alone.
Lumbar interbody fusion — PRP aids bone healing and decreases the rate of pseudoarthrosis.
Adhesive capsulitis shows a genuinely useful split: corticosteroid gave better short-term pain and function, PRP better long-term reduction in pain and disability. Since adhesive capsulitis is self-limiting but prolonged, the choice depends on which part of the curve you are trying to shorten.
Knee osteoarthritis is less settled than the marketing suggests, and is covered in PRP for knee osteoarthritis.
On alpha-2-macroglobulin, Stall reports a prospective trial at NYU Langone in which 75 patients with symptomatic knee osteoarthritis were randomised to intra-articular steroid, traditional PRP, or A2M. A2M had similar efficacy to corticosteroid and was “no better than regular PRP” at six and twelve weeks. Worth knowing before paying a premium for it.
How many injections, and how far apart
The honest answer is that the ideal regimen is undefined, and Stall says so: “the ideal injection regimen remains undefined and there are contradictions within the published literature.”
What can be said: healing after PRP does not begin until several weeks after injection, so common clinical practice is not to inject more often than once a month. Because remodelling continues for a year or longer, there is no contraindication to injecting less frequently.
He is equally candid about the limits of the multiple-injection studies. One comparison suggested three consecutive PRP injections outperformed a single injection or three hyaluronic acid injections at six months — but the single-injection group received two saline injections first, an unexplained design choice of unknown effect, in a small sample that has not been replicated.
The regulatory line: 21 CFR 1271
What is legal here changed, and the change is recent enough that older guidance circulating online is wrong.
Before 31 May 2021 the FDA operated a discretionary enforcement period during which providers and manufacturers had considerably more latitude to market unapproved products. That period ended.
Two tests govern what remains permissible. Minimal manipulation: concentrating cells by centrifugation, as in PRP, passes — the criterion, in Stall's framing, is that “you are not creating something new.” Cell culture expansion in a laboratory medium is more than minimal manipulation and fails. Homologous use: transplanted tissue must perform the same basic function in the recipient as in the donor.
The practical consequence most often missed: adipose-derived stem cell products for cushioning and support are no longer permitted under current FDA guidance. A clinic still advertising them is not operating under the current rules.
For clinicians
Preparation technique, patient selection and injection technique are learned under supervision. Empire teaches PRP and regenerative technique across the pain management academy.
Learn blocks with your hands, not from a page
Empire’s Pain Management Training (THE Pain Show) is accredited for 25.25 AMA PRA Category 1 Credits™, jointly provided by AKH, Inc, and Empire Medical Training. For narrower peripheral work, Joint, Extremity and Non-Spinal Injection Training carries 6.75 credits for the complete in-person hybrid program, and Advanced Musculoskeletal Ultrasound Guided Injections builds the guidance skills above.
Claim Your Prize!